Outcomes of Patients Hospitalized With Community-Acquired, Health Care–Associated, and Hospital-Acquired Pneumonia

Mario Venditti, MD; Marco Falcone, MD; Salvatore Corrao, MD; Giuseppe Licata, MD; Pietro Serra, MD; and the Study Group of the Italian Society of Internal Medicine*

Background: Traditionally, pneumonia has been classified as either community- or hospital-acquired. Although only limited data are available, health care–associated pneumonia has been recently proposed as a new category of respiratory infection. “Health care–associated pneumonia” refers to pneumonia in patients who have recently been hospitalized, had hemodialysis, or received intravenous chemotherapy or reside in a nursing home or long-term care facility.

Objective: To ascertain the epidemiology and outcome of community-acquired, health care–associated, and hospital-acquired pneumonia in adults hospitalized in internal medicine wards.

Design: Multicenter, prospective observational study.

Setting: 55 hospitals in Italy comprising 1941 beds.

Patients: 362 patients hospitalized with pneumonia during two 1-week surveillance periods.

Measurements: Cases of radiologically and clinically assessed pneumonia were classified as community-acquired, health care–associated, or hospital-acquired and rates were compared.

Results: Of the 362 patients, 61.6% had community-acquired pneumonia, 24.9% had health care–associated pneumonia, and 13.5% had hospital-acquired pneumonia. Patients with health care–associated pneumonia had higher mean Sequential Organ Failure Assessment scores than did those with community-acquired pneumonia (3.0 vs. 2.0), were more frequently malnourished (11.1% vs. 4.5%, and had more frequent bilateral (34.4% vs. 19.7%) and multilobar (27.8% vs. 21.5%) involvement on a chest radiograph. Patients with health care–associated pneumonia also had higher mortality rates (17.8% [CI, 10.6% to 24.9%] vs. 6.7% [CI, 2.9% to 10.5%]) and longer mean hospital stay (18.7 days [CI, 15.9 to 21.5 days] vs. 14.7 days [CI, 13.4 to 15.9 days]). Logistic regression analysis revealed that depression of consciousness (odds ratio [OR], 3.2 [CI, 1.06 to 9.8]), leukopenia (OR, 6.2 [CI, 1.01 to 37.6]), and receipt of empirical antibiotic therapy not recommended by international guidelines (OR, 6.4 [CI, 2.3 to 17.6]) were independently associated with increased in-hospital mortality.

Limitations: The number of patients with health care–associated pneumonia was relatively small. Microbiological investigations were not always homogeneous. The study included only patients with pneumonia that required hospitalization; results may not apply to patients treated as outpatients.

Conclusion: Health care–associated pneumonia should be considered a distinct subset of pneumonia associated with more severe disease, longer hospital stay, and higher mortality rates. Physicians should differentiate between patients with health care–associated pneumonia and those with community-acquired pneumonia and provide more appropriate initial antibiotic therapy.

Funding: None.


See also:

Print
Editors’ Notes............................................ 20
Summary for Patients.................................. I-36

Web-Only
Appendix
Appendix Tables
Conversion of graphics into slides

© 2009 American College of Physicians

Pneumonia represents a spectrum of diseases that range from community-acquired to hospital-acquired and ventilator-associated pneumonia. Despite advances in diagnosis, antimicrobial therapy, and supportive care, pneumonia remains an important cause of morbidity and mortality, especially in patients who require hospitalization (1).

In recent years, changes in the health care system have shifted a considerable part of patient care from hospitals to the community. As a result, the traditional distinction between community- and hospital-acquired infections has become less clear. Infections occurring among outpatients in contact with the health care system have been termed “health care–associated infections” (2).

The 2005 American Thoracic Society and Infectious Diseases Society of America guidelines (3) propose a new category of pneumonia: health care–associated pneumonia. This category includes patients with pneumonia who have had recent contact with the health care system through nursing homes, hemodialysis clinics, or hospitalization (3, 4). However, limited data exist to validate this proposal. The largest studies supporting the proposal are 2 retrospec-

The largest studies supporting the proposal are 2 retrospec-

However, limited data exist to validate this proposal.
We sought to ascertain the epidemiology and outcome of community-acquired, health care–associated, and hospital-acquired pneumonia in patients hospitalized in Italian internal medicine wards and to better characterize these clinical entities in a large, national cohort.

**Methods**

**Setting and Study Period**

This cohort study, open to all members of the Italian Society of Internal Medicine, was performed prospectively in 59 divisions of internal medicine in 55 Italian hospitals (18 teaching and 37 community hospitals, comprising 1941 beds). All members of the Italian Society of Internal Medicine were informed about the study by e-mail or telephone (the protocol and design of the study were also available on the Society’s Web site, www.simi.it, and in its official journal). Participation was free and spontaneous. As shown in Figure 1, participating centers were geographically distributed across most regions of Italy. Cases of pneumonia were assessed during 2 active 1-week surveillance periods (22 to 29 January 2007 and 25 June to 2 July 2007). The study included adults (>18 years) already hospitalized with pneumonia and those who were newly admitted during the study periods (incident cases). An institutional review board of the Board of the Italian Society of Internal Medicine approved this study.

**Patients**

Our case definition was radiologic evidence of pneumonia and at least 2 of the following criteria: fever or hypothermia (temperature >38 °C or <35 °C), dyspnea, cough and purulent sputum, pleuritic chest pain, or signs of consolidation on respiratory auscultation. Our definition of hospital-acquired pneumonia also included the absence of pulmonary infiltrates on a chest radiograph at the time of hospital admission.

We classified patients as having health care–associated pneumonia if they had attended a hospital or hemodialysis clinic or received intravenous chemotherapy in the past 30 days, had been admitted to an acute-care hospital for at least 2 days or had surgery in the past 180 days, or resided in a nursing home or long-term care facility. We classified patients as having hospital-acquired pneumonia if they received their diagnosis after being hospitalized for more than 72 hours or within 10 days of leaving the hospital. We considered patients who fulfilled the criteria for health care–associated pneumonia but developed pneumonia in the 10 days after discharge as having hospital-acquired pneumonia. We classified patients as having community-acquired pneumonia if they did not fit the criteria for either health care–associated or hospital-acquired pneumonia.

Exclusion criteria included acquisition of pneumonia in the intensive care unit or in another hospital and HIV infection.

**Measurements**

To stratify patients into risk classes, we used the prediction rule calculated according to the Pneumonia Severity Index and the CURB-65 (Confusion, Urea nitrogen, Respiratory rate, Blood pressure, and age 65 years or older) score (8, 9).

We recorded the following data: age; sex; intrinsic and extrinsic risk factors, such as underlying diseases, pharma-
colologic immunosuppression (steroids and cytotoxic drugs), leukopenia, previous antibiotic therapy, use of histamine-2 blockers or antacids, nebulization, previous invasive techniques (such as endotracheal intubation or tracheotomy), surgery, or malnutrition; clinical signs and symptoms, such as cough, dyspnea, chest pain, body temperature, respiratory rate, heart rate, arterial systolic and diastolic blood pressure, and depression of consciousness; results of laboratory studies, such as blood gas analysis, leukocyte count, platelet count, serum creatinine level, and total and fractionated bilirubin; chest radiography pattern, such as lateral or bilateral involvement, number of lobes affected, and presence of pleural effusion; results of microbiological studies, such as sputum culture, blood culture, urinary antigen detection, pleural fluid culture, and bronchoalveolar lavage culture; antibiotic therapy; and outcome. We also recorded in-hospital complications and deaths. At the clinical end points of hospital discharge or death, we retrieved data on in-hospital death, length of hospital stay, and adequacy of initial antimicrobial treatment.

We defined empirical antibiotic therapy as antibiotics administered on the first day of therapy for pneumonia and considered an empirical antibiotic regimen as adherent to guidelines if it was concordant with the available American Thoracic Society and Infectious Diseases Society of America guidelines for community-acquired, hospital-acquired, or health care–associated pneumonia (3, 12). We rated an antimicrobial regimen as inadequate if 1 or more of the criteria for lower respiratory tract pathogens. We rated an antimicrobial regimen as inadequate if 1 or more of the etiologic diagnosis according to susceptibility test criteria for lower respiratory tract pathogens. We rated an antimicrobial treatment as inadequate if 1 or more of the organisms present were known to have intrinsic resistance or were found to be resistant through susceptibility testing. For cases in which *Pseudomonas aeruginosa* was isolated, we considered treatment adequate only if the patient received combination treatment with at least 2 drugs to which the strain was fully susceptible (13).

### Statistical Analysis

Data are presented as mean values (95% CI) for quantitative variables and as relative frequencies (95% CI) for categorical variables. We performed nonparametric or equivalent tests for group comparison of quantitative variables: the Mann–Whitney *U* test for 2-group comparisons, 1-way analysis of variance on the ranks of observations for 3-group mean value comparisons, and post hoc Bonferroni correction for pairwise comparisons. We used the Pearson chi-square test and the generalized Fisher exact test for contingency table analysis. We investigated the association among pneumonia classes (as a dependent multinomial 3-level variable) and the other categorical variables by using multinomial logistic regression. After bivariate analyses, we selected independent variables at a *P* value less than 0.100. All were put into a model of multivariate multinomial logistic regression analysis. We used the community-acquired pneumonia category as a reference for comparisons. Finally, we performed logistic regression for binary outcomes to analyze the association between variables and mortality and used the Hosmer–Lemeshow methodology for variable selection (14). We then put all the selected variables into the multivariate model. We performed the Pearson goodness-of-fit test to assess the overall fit of the model. We computed odds ratios (ORs), derived from the covariates, and confidence intervals. We used a bootstrap procedure to resample observations (1000 replications per time) according to hospital ward clusters for both descriptive and inferential analyses. A 2-tailed *P* value less than 0.050 was considered statistically significant. We used STATA/SE, version 9.2 for Windows (StataCorp, College Station, Texas), to analyze the data.

### Role of the Funding Source

Our study received no external funding.

### RESULTS

#### Patient Characteristics

Figure 2 shows the flow of study participants. The sample included 362 patients with pneumonia—271 hospitalized during the first week and 91 during the second week of study. The number of cases detected in each center ranged from 1 to 26. The prevalence of pneumonia was 11.9% (CI, 11.2% to 12.6%) during the winter period (22 to 29 January 2007) and 4.7% (CI, 4.2% to 5.2%) during the summer period (25 June to 2 July 2007).

Most patients (60.2%) were men, and the mean age was 75.5 years. The most frequently encountered comorbid conditions were chronic obstructive pulmonary disease (36.2%), heart failure (30.7%), dementia (24%), diabetes mellitus (21%), renal failure (20.7%), and cancer (18.8%). At the time of diagnosis of pneumonia, 176 (48.6%) patients had at least 2 comorbid conditions and 80 (22.1%) had more than 2 comorbid conditions. Overall, 223 (61.6%) patients had community-acquired pneumonia, 90 (24.9%) had health care–associated pneumonia, and 49...
(13.5%) had hospital-acquired pneumonia. First- and second-week patient populations did not significantly differ in terms of demographic characteristics, comorbid conditions, category of pneumonia, or outcome (data not shown).

**Tables** 1 and 2 compare the characteristics of patients with community-acquired pneumonia, health care–associated pneumonia, and hospital-acquired pneumonia. **Table** 3 lists the criteria for inclusion in the health care–associated pneumonia group. **Appendix Tables** 1, 2, and 3 (available at www.annals.org) show the analysis of incident cases only.

Compared with patients with community-acquired pneumonia, those with health care–associated pneumonia were more commonly in high-risk pneumonia severity index classes (**Table** 1), had a higher incidence of malnutrition, and had more frequent bilateral involvement during radiographic examination (**Table** 2). In addition, patients with health care–associated pneumonia received gastric acid–reducing agents or aerosolized drugs more frequently and were febrile at hospital admission less frequently than patients with community-acquired pneumonia. However, the 2 groups did not significantly differ in terms of mean age, sex, or the presence of comorbid conditions. At the time of diagnosis, patients with community-acquired pneumonia had significantly lower mean Sequential Organ Failure Assessment scores (2.0 [CI, 1.7 to 2.3]) than did patients with health care–associated (3.0 [CI, 2.6 to 3.4]) or hospital-acquired pneumonia (2.8 [CI, 2.4 to 3.2]).

A significantly higher percentage of patients with hospital-acquired pneumonia had leukopenia, multilobar infiltrates, a tracheostomy procedure, or a history of recent endotracheal intubation than did those with community-acquired or health care–associated pneumonia (**Table** 2).

We analyzed categorical variables by using a multivariate model that included age, length of hospital stay, duration of antibiotic therapy, etiologic diagnosis, presence of at least 2 comorbid conditions, malnutrition, therapy with histamine-2 blockers or antacids, aerosolized drug therapy, fever, cough, bilateral or multilobar involvement at chest radiograph, monotherapy, antibiotic therapy adherent to international guidelines, appropriateness of antibiotic therapy, and death. Multinomial logistic regression showed that histamine-2 blocker or antacid administration (relative risk ratio [RRR], 3.3 [CI, 1.6 to 7.1];  \( P = 0.002 \) ), hospital stay longer than 20 days (RRR, 2.7 [CI, 1.2 to 6.2];  \( P = 0.010 \) ), and receipt of an empirical antibiotic not recommended by international guidelines (RRR, 4.1 [CI, 1.6 to 10.4];  \( P = 0.004 \) ) were independently associated with health care–associated pneumonia (compared with community-acquired pneumonia). Histamine-2 blocker or antacid administration (RRR, 8.9 [CI, 2.3 to 34.5];  \( P = 0.002 \) ) and hospital stay longer than 20 days (RRR, 5.3 [CI, 2.2 to 12.4];  \( P < 0.001 \) ) were independently associated with hospital-acquired pneumonia (compared with community-acquired pneumonia).

**Antimicrobial Therapy and Outcomes**

**Table** 4 shows data on antimicrobial therapy and outcomes of the 3 pneumonia groups. Overall, 189 (52.2%) patients received an initial empirical therapy according to international guidelines. Patients with health care–associated pneumonia were more frequently treated with an empirical therapy that was not consistent with available guidelines ( \( P < 0.001 \) ).

The mean duration of antibiotic therapy and length of hospital stay were also significantly higher in patients with health care–associated pneumonia than in those with community-acquired pneumonia. The mortality rate associated with community-acquired pneumonia...
was significantly lower than that for health care–associated pneumonia (17.8% [CI, 10.6% to 24.9%]) or hospital-acquired pneumonia (18.4% [CI, 6.4% to 30.3%]).

In the bivariate analysis, the following factors were significantly associated with in-hospital death: leukopenia, malnutrition, depression of consciousness, pleuritic chest pain, bilateral and multilobar involvement on chest radiography, pleural effusion, inclusion in the health care–associated or hospital-acquired pneumonia group, antibiotic therapy not consistent with recommended guidelines, inappropriate therapy, microbiologic diagnosis, and a Sequential Organ Failure Assessment score greater than 2. When all of the selected variables were put into the multivariate model, 3 factors were independently associated with death: depression of consciousness (OR, 3.2 [CI, 1.06 to 9.8]), leukopenia (OR, 6.2 [CI, 1.01 to 37.6]), and receipt of an empirical antibiotic not recommended by international guidelines (OR, 6.4 [CI, 2.3 to 17.6]).

**DISCUSSION**

To our knowledge, this is the first prospective, observational, multicenter study that compares the epidemiology and outcome of community-acquired pneumonia, health care–associated pneumonia, and hospital-acquired pneumonia in patients hospitalized in medical wards. Our findings, which may be considered representative of all Italian hospitals, support a new pneumonia classification scheme that distinguishes among community-acquired, health care–associated, and hospital-acquired pneumonia. Compared with community-acquired pneumonia, health care–associated pneumonia is associated with longer hospital stay and higher risk for a fatal complication. Health care–associated pneumonia also differs from hospital-acquired pneumonia that occurs in nonventilated patients; however, in general, health care–associated pneumonia differs from hospital-acquired pneumonia to a lesser degree.

### Table 2. Patient Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Community-Acquired Pneumonia (n = 223)</th>
<th>Health Care–Associated Pneumonia (n = 90)</th>
<th>Hospital-Acquired Pneumonia (n = 49)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men, %</td>
<td>58.8</td>
<td>62.2</td>
<td>63.3</td>
<td>0.78</td>
</tr>
<tr>
<td>Mean age, y</td>
<td>73.9</td>
<td>77.4</td>
<td>79.9</td>
<td>0.060</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease, %</td>
<td>39.0</td>
<td>30.0</td>
<td>34.7</td>
<td>0.45</td>
</tr>
<tr>
<td>Heart failure, %</td>
<td>27.8</td>
<td>37.7</td>
<td>30.6</td>
<td>0.25</td>
</tr>
<tr>
<td>Dementia, %</td>
<td>22.4</td>
<td>21.1</td>
<td>36.7</td>
<td>0.25</td>
</tr>
<tr>
<td>Renal failure, %</td>
<td>18.4</td>
<td>25.5</td>
<td>22.4</td>
<td>0.29</td>
</tr>
<tr>
<td>Diabetes mellitus, %</td>
<td>17.5</td>
<td>26.7</td>
<td>26.5</td>
<td>0.150</td>
</tr>
<tr>
<td>Cancer, %</td>
<td>15.7</td>
<td>25.5</td>
<td>20.4</td>
<td>0.140</td>
</tr>
<tr>
<td>Chronic liver disease, %</td>
<td>8.1</td>
<td>12.2</td>
<td>10.2</td>
<td>0.55</td>
</tr>
<tr>
<td>≥2 comorbid conditions, %</td>
<td>18.4</td>
<td>28.9</td>
<td>26.5</td>
<td>0.080</td>
</tr>
<tr>
<td>≥2 comorbid conditions, %</td>
<td>44.4</td>
<td>52.2</td>
<td>61.2</td>
<td>0.030*</td>
</tr>
<tr>
<td>Endotracheal intubation in the past 30 days, %</td>
<td>0</td>
<td>2.2</td>
<td>12.2</td>
<td>&lt;0.001**†</td>
</tr>
<tr>
<td>Leukopenia, %</td>
<td>3.6</td>
<td>4.4</td>
<td>12.2</td>
<td>0.89</td>
</tr>
<tr>
<td>Malnutrition, %</td>
<td>4.5</td>
<td>11.1</td>
<td>16.3</td>
<td>0.004**†</td>
</tr>
<tr>
<td>Histamine-2 blockers or antacids, %</td>
<td>23.3</td>
<td>53.3</td>
<td>57.1</td>
<td>&lt;0.001**†</td>
</tr>
<tr>
<td>Tracheostomy, %</td>
<td>0</td>
<td>1.1</td>
<td>8.2</td>
<td>&lt;0.001*†</td>
</tr>
<tr>
<td>Aerosolized drugs, %</td>
<td>12.5</td>
<td>26.7</td>
<td>22.4</td>
<td>0.003†</td>
</tr>
<tr>
<td>Previous antibiotic therapy, %</td>
<td>32.7</td>
<td>38.9</td>
<td>42.8</td>
<td>0.26</td>
</tr>
<tr>
<td>Fever, %</td>
<td>62.8</td>
<td>45.5</td>
<td>49</td>
<td>0.020†</td>
</tr>
<tr>
<td>Depression of consciousness, %</td>
<td>19.8</td>
<td>26.7</td>
<td>32.6</td>
<td>0.160</td>
</tr>
<tr>
<td>Dyspnea, %</td>
<td>69</td>
<td>70.0</td>
<td>49</td>
<td>0.060</td>
</tr>
<tr>
<td>Cough, %</td>
<td>61.3</td>
<td>61.1</td>
<td>46.9</td>
<td>0.180</td>
</tr>
<tr>
<td>Purulent sputum, %</td>
<td>32</td>
<td>36.7</td>
<td>34.7</td>
<td>0.63</td>
</tr>
<tr>
<td>Pleuritic chest pain, %</td>
<td>17.1</td>
<td>12.2</td>
<td>4.1</td>
<td>0.60</td>
</tr>
<tr>
<td>Leukocytosis, %</td>
<td>54.3</td>
<td>52.2</td>
<td>53.1</td>
<td>0.94</td>
</tr>
<tr>
<td>Bilateral involvement on chest radiograph, %</td>
<td>19.7</td>
<td>34.4</td>
<td>32.6</td>
<td>0.007**†</td>
</tr>
<tr>
<td>Multilobar infiltrates, %</td>
<td>21.5</td>
<td>27.8</td>
<td>38.8</td>
<td>0.020*</td>
</tr>
<tr>
<td>Pleural effusion, %</td>
<td>38.7</td>
<td>45.5</td>
<td>38.8</td>
<td>0.56</td>
</tr>
</tbody>
</table>

* P < 0.05 for comparison between hospital-acquired and community-acquired pneumonia.
† P < 0.05 for comparison between health care–associated and community-acquired pneumonia.

### Table 3. Criteria for Inclusion in the Health Care–Associated Pneumonia Group

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Patients (95% CI), % (n = 90)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recent hospitalization within 180 days</td>
<td>80 (75.8–84.2)</td>
</tr>
<tr>
<td>Nursing home resident</td>
<td>10 (6.8–13.2)</td>
</tr>
<tr>
<td>Hemodialysis</td>
<td>3.3 (1.4–5.2)</td>
</tr>
<tr>
<td>Intravenous chemotherapy in the 30 days before pneumonia</td>
<td>6.7 (4.1–9.3)</td>
</tr>
</tbody>
</table>
than from community-acquired pneumonia because the severity of disease and mortality rates are more similar to the former. These results suggest that community-acquired pneumonia, health care–associated pneumonia, and hospital-acquired pneumonia are 3 distinct epidemiologic and clinical entities, with a trend toward increasing disease severity from the first to the last group.

The poor prognosis observed in patients with health care–associated pneumonia seems to be related to greater severity of disease (demonstrated by higher mean Sequential Organ Failure Assessment scores and by more frequent bilateral and multilobar lung involvement). The 3 groups did not significantly differ in terms of mean age or the presence of comorbid conditions. This probably reflects the homogeneity of our sample, because patients hospitalized in internal medicine departments typically have multiple comorbid conditions, higher mean age, and a longer hospital stay than those admitted to other departments (such as oncology or hematology units) or surgical wards. However, patients with health care–associated pneumonia had more comorbid conditions than patients with community-acquired pneumonia (although the differences were not statistically significant, possibly because of sample size limitations); this finding may also explain the higher severity of clinical conditions observed in the health care–associated pneumonia group. Patients with health care–associated pneumonia were also less frequently febrile at admission and were more frequently malnourished and treated with gastric acid-suppressive agents or aerosolized drugs than patients with community-acquired pneumonia. On the other hand, a significantly higher proportion of patients with hospital-acquired pneumonia had a tracheostomy procedure, a history of recent endotracheal intubation, and leukopenia. Overall, patients with hospital-acquired pneumonia seemed the most critically ill.

In Tables 1 and 4, the groups differ significantly for some outcomes, but the CIs of the mean estimates overlap. This is probably because of in-hospital clustering effects. Methods that account for the clustering, such as our bootstrapping procedure, can lead to more efficient estimates of the differences than of the mean values themselves. Thus, the comparisons are robust enough to warrant discussion.

Although the 2005 guidelines from the American Thoracic Society and Infectious Diseases Society of America (3) included specific recommendations for the current management of health care–associated pneumonia, we observed low adherence to available guidelines. Physicians usually do not differentiate between the initial treatment for health care–associated pneumonia and community-acquired pneumonia, and this clinical approach usually results in inappropriate initial therapy and increased mortality. Indeed, regression analysis indicated that administration of empirical antibiotic therapy not recommended in the guidelines was independently associated with increased mortality.

A MEDLINE search of the English-language medical literature using the terms “health care–associated” and “pneumonia” revealed only a few original articles (5–7), most of them retrospective studies (5, 6). The definition of health care–associated infections was initially proposed by Friedman and colleagues (2), who chose previous hospitalization within 3 months of the study as the criterion by which to categorize patients as having a health care–associated bloodstream infection. Other investigators extended the criterion of community-onset health care–associated infections to include hospitalization in the preceding 12 months (15). The definition of health care–associated pneumonia has been adapted from the criteria described for bloodstream infections. In the first retrospective study on culture-positive pneumonia conducted in the United States (5), which used a large multi-institutional database, the case definition of health care–associated pneumonia required any of the following criteria: residence in a health care facility, long-term hemodialysis, or hospitalization within 30 days of receiving a diagnosis of pneumonia. In a prospective analysis of patients with community-onset pneumonia requiring hospitalization, Carratala and colleagues (7) extended the duration criteria of previous hospitalization to 90 days before diagnosis, which is also recommended by the American Thoracic Society and the Infectious Diseases Society of America guidelines (3). In our study, we used 180 days as a cutoff for recent hospitalization to differentiate between community-acquired and health care–associated pneumonia. We based our choice to expand the inclusion criteria for health care–

---

Table 4. Antimicrobial Therapy and Outcomes

| Variable                                      | Community-Acquired Pneumonia (n = 223) | Health Care–Associated Pneumonia (n = 90) | Hospital-Acquired Pneumonia (n = 49) | P Value  
|-----------------------------------------------|---------------------------------------|------------------------------------------|-------------------------------------|----------
| Initial antibiotic monotherapy (95% CI), %    | 54.9 (47.7 to 62.2)                   | 60.7 (48.1 to 73.2)                     | 28.6 (14.7 to 42.4)                 | 0.010*   
| Adherence to international guidelines (95% CI), % | 58.7 (51.8 to 65.6)                   | 26.7 (16.5 to 36.8)                     | 69.4 (57 to 81.8)                   | <0.001†  
| Inappropriate antibiotic therapy (95% CI), % | 5.8 (2.1 to 9.5)                      | 18.9 (10 to 27.8)                       | 10.2 (2.6 to 23)                    | 0.020†   
| Mean duration of antibiotic therapy (95% CI), d | 13.8 (12.9 to 14.7)                   | 16.1 (14.6 to 17.7)                     | 16.7 (14.3 to 19.1)                 | 0.010†   
| Mean duration of hospitalization (95% CI), d | 14.7 (13.4 to 15.9)                   | 18.7 (15.9 to 21.5)                     | 24.8 (19.8 to 29.8)                 | <0.001‡  
| Overall in-hospital mortality rate (95% CI), % | 6.7 (2.9 to 10.5)                     | 17.8 (10.6 to 24.9)                     | 18.4 (6.4 to 30.3)                  | 0.020†   

* P < 0.05 for comparison between hospital-acquired and community-acquired pneumonia.
† P < 0.05 for comparison between health care–associated and community-acquired pneumonia.
Health Care–Associated Pneumonia as a Distinct Subset of Pneumonia

Our study has several limitations. First, it was a pragmatic study that included both tertiary and secondary care centers. Microbiological investigation was therefore neither homogeneous nor extensively performed in all cases. Second, the number of patients with health care–associated pneumonia was relatively small. Finally, we included only patients with pneumonia that required hospitalization; thus, our results may not apply to patients treated as outpatients. Future prospective studies are needed to clarify the microbiology of health care–associated pneumonia in hospitalized patients. Moreover, the importance of the new pneumonia classification will rest on randomized and observational studies that demonstrate improved outcomes for patients with health care–associated pneumonia managed with guidelines specific to health care–associated pneumonia.

Our data provide further evidence that health care–associated pneumonia is usually not recognized or managed correctly by clinicians, possibly resulting in inappropriate antibiotic therapy and increased mortality. The selection of empirical antibiotics for health care–associated pneumonia should include coverage of methicillin-resistant \textit{S. aureus} and multidrug-resistant gram-negative rods (such as linezolid or glycopeptides plus an antipseudomonal \beta-lactam), as recommended by the consensus of Infectious Diseases Society of America experts (18).

In conclusion, health care–associated pneumonia represents a distinct subset of pneumonia. Compared with patients who have community-acquired pneumonia, patients with health care–associated pneumonia have more severe disease, prolonged hospitalization, and increased mortality. Consequently, health care–associated pneumonia is more similar to hospital-acquired pneumonia than community-acquired pneumonia and requires specific initial empirical antibiotic therapy. Physicians should differentiate between patients with health care–associated pneumonia and those with community-acquired pneumonia to provide optimal clinical management.

From the University of Rome, Rome, Italy, and Università degli Studi di Palermo, Palermo, Italy.

\textbf{Acknowledgment:} The authors thank Professor Pier Mannuccio Mannucci, Milan, Italy, for his activity as Chief of the Italian Society of Internal Medicine group for independent clinical research. They also thank Sohita Dhillon and Rod McNab of Wolters Kluwer Health for English-language assistance in the preparation of this manuscript.

\textbf{Potential Financial Conflicts of Interest:} Consultancies: M. Venditti (Glaxo Wellcome, Gilead, Angelini, Novartis, Pfizer, Bayer, Wyeth).

\textbf{Grants received:} M. Falcone (Pfizer).

\textbf{Reproducible Research Statement:} Study protocol: Available at www.simil.it. Statistical code: Available from Dr. Corrao (s.corrao@unipa.it).

\textbf{Data set:} Not available.

\textbf{Requests for Single Reprints:} Mario Venditti, MD, Dipartimento di Medicina Clinica—Policlinico Umberto I, Università di Roma “La Sapienza,” Viale dell’Università 37, 00161 Rome, Italy; e-mail, mario.venditti@uniroma1.it.

Current author addresses and author contributions are available at www.annals.org.
References
Current Author Addresses: Drs. Venditti, Falcone, and Serra: Dipartimento di Medicina Clinica—Policlinico Umberto I, Università di Roma “La Sapienza,” Viale dell’Università 37, 00161 Rome, Italy.
Drs. Corrao and Licata: Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli Studi di Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy.

Author Contributions: Conception and design: M. Venditti, M. Falcone, P. Serra.
Analysis and interpretation of the data: M. Venditti, M. Falcone, S. Corrao.
Drafting of the article: M. Venditti, M. Falcone.
Critical revision of the article for important intellectual content: S. Corrao, G. Licata.
Final approval of the article: S. Corrao, G. Licata, P. Serra.
Provision of study materials or patients: G. Licata.
Statistical expertise: S. Corrao.
Obtaining of funding: G. Licata.
Administrative, technical, or logistic support: G. Licata.
Collection and assembly of data: M. Falcone, S. Corrao.

APPENDIX: PARTICIPATING MEMBERS OF THE ITALIAN SOCIETY OF INTERNAL MEDICINE

Medicina Interna, Policlinico San Donato Milanese:
Francesco Salerno.

Dipartimento di Scienze Cliniche, Policlinico Umberto I—Università di Roma “La Sapienza”: Sebastiano Filetti, Emilio D’Erasmo.

II Patologia Medica, Policlinico Umberto I—Università di Roma “La Sapienza”: Filippo Rossi Fanelli.

Geriatría, Ospedale Civile, Montefiascone: Alessandra Fiorentini, Luigi Cricco.

Medicina Interna 5, Azienda Ospedaliera San Camillo-Forlanini, Roma: Laura Gasbarrone, Cecilia Serafini.

Clinica Medicina Interna 3, Azienda Ospedaliera Universitaria San Martino, Genova: Riccardo Ghio, Gabriele Zoppoli.

Medicina Generale III, Ospedale Luigi Sacco, Milano: Michele Cortellaro, Marina Magenta.

Medicina Generale I, Azienda Ospedaliera Università degli Studi di Siena: Ranuccio Nuti, Roberto Valenti.

Presidio Ospedaliero C. Ondoli, Angera: Vincenzo Milano.

Medicina Interna, Azienda Ospedaliera San Giovanni Addolorata, Roma: Camillo Brandimarte, Paolo Carfagna.

Divisione Medicina Interna e Specialistica, Policlinico Universitario, Palermo: Riccardo Di Sciacca, Antonio Tuttolomondo.

Unità Operativa Medicina, Azienda Ospedaliera Cardiologico G. Panico, Tricase: Maria Grazia Serra.

Semeiotica Medica, Policlinico S. Orsola Malpighi, Bologna: Mauro Bernardi, Silvia Li Bassi.

Dipartimento Medicina Interna e Gastroenterologia, Policlinico S. Orsola Malpighi, Bologna: Vincenzo Stanghellini, Elena Boschi.

Medicina Interna Universitaria “Cesare Frugoni”, Policlinico, Bari: Salvatore Antonaci, Francesco Vella.

Dipartimento di Medicina Interna—Policlinico Universitario “G. Martino” di Messina: Antonino Catalano.

Divisione Medicina, Azienda Ospedaliera Universitaria, Modena: Maria Luisa Zeneroli, Elisabetta Ascarì, Alberto Veggetti.

Ospedale del Delta, Lagoaonto: Roberto Manfredini, Susanna Gamberonì.

Istituto di Clinica Medica Generale, Ospedale di Cattinara, Trieste: Gianfranco Guarnieri, Angela Fioretto.

Medicina Interna, Ospedale “G. Mazzini” ASL Teramo: Dario Di Michele, Domenico Parisi.

Divisione di Medicina Interna, Ospedale Civile, Casorate Primo: Nicola Lucio Liberato, Esio Ronchi.

Medicina Interna, Ospedale Civile, Senigallia: Simonetta Sturbini, Paolo Canafoglia.

Medicina Interna Ospedaliera, Azienda Ospedaliera Universitaria Sant’Anna, Ferrara: Massimo Gallerani, Benedetta Boari.

Medicina ad Alta Rotazione, Azienda Ospedaliera Universitaria Sant’Anna, Ferrara: Ingrid Nielsen.

Geriatría, Azienda Ospedaliera San Gerardo, Monza: Giorgio Annoni, Anna Rossetti.

Azienda Ospedaliera Ospedale di Circolo Fondazione Macchi, Varese: Matteo Bernasconi.

Medicina Interna, Azienda Ospedaliera Policlinico Bari: Carmela Giannatempo.

Medicina I, Azienda Ospedaliera G. Salvini, Garbagnate Milanese: Roberta Turconi, Maurizio Colombo.

Medicina Interna 2, Policlinico Ospedale Maggiore, Milano: Alberto Tedeschi, Raffaella Rossio.

Medicina Interna II, Policlinico S. Maria alle Scotte, Siena: Roberto Cappelli, Valentina Guidi.

Medicina 1 A.S.L. 2 Savonese Ospedale San Paolo, Savona: Rodolfo Tassara, D. De Melis.

Medicina Interna, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano: Roberto Cosenzini, Margherita Arioli, Francesco Salerno, Giulia Gobbo.

Medicina Generale, A.S.L. 17, Ospedale di Este: Fabio Presotto, Sergio Gallana.

Clinica Medica III, Fondazione IRCCS Policlinico San Matteo Università di Pavia: Carlo Balduini, Giampiero Bertolino.

Medicina Interna, Presidio Ospedaliero—A.S.L. BA/5, Monopoli-Conversano: Giacomo Fera.

Clinica Medica I, Policlinico San Matteo, Pavia: Gino Roberto Corazza, Ida Capriglione.

Medicina, Presidio Sanitario Gradenigo, Torino: Giulia Pilerio.

Dipartimento di Medicina Interna—Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena & Università degli studi di Milano: Maria Domenica Cappellini, Giovanna Fabio, Maria Carrabba.

Medicina Generale, Ospedale E. Bassini, Cinisello Balsamo, Azienda Ospedaliera S. Gerardo, Monza: Sheng Chin Wu, Maria Beatrice Secchi.

Medicina, Casa di Cura La Madonnina, Bari: Michele Leone.

Medicina Interna, Presidio Ospedaliero, Pescara: Lucrezia De Feudis.

Medicina Interna Ospedale San Salvatore Peauro: Massimo Gunelli, Orazio Ferri.

Medicina Interna 2, Presidio Ospedaliero Cà Fondello, Trevixo: Carlo Doroldi, Roberta Pistas.

Università Vita-Salute San Raffaele–Milano: Maria Grazia Sabbadini, Moreno Tresoldi.
Medicina Interna 5, Ospedale Unico della Versilia, Lido di Camaiore: Paola Lambelet, Stefano Fascetti.

Struttura Complessa di Medicina Interna, A.O. Ospedale di Lecco, P.O. di Merate: Massimo Vanoli, Gianluca Casella.

Clinica Medica Generale, Azienda Ospedali Civili, Brescia: Enrico Agabiti Rosei, Andrea Salvi.

Medicina Interna, Ospedale Civile dell’Annunziata, Cosenza: Alfonso Noto.

Medicina Interna, Ospedale San Giovanni Decollato-Andosilla, Cività Castellana: Antonio Perciaccante.

Medicina Interna, Ospedale Madre G. Vannini, Roma: Claudio Santini, Maurizia Galiè.

Istituto di Medicina Interna e Geriatria, Università Cattolica del Sacro Cuore, Policlinico A. Gemelli, Roma: Giovanni Gasbarrini, Antonio Grieco.

Medicina I, Azienda Ospedaliera di Busto Arsizio (VA) Ospedale di Circolo di Busto Arsizio: Barbara Nardi.

Clinica Medica 1, Azienda Ospedaliera, Padova: Aldo Gaetano Baritussio, Roberto Vannuccini.

Medicina Generale, Alessandria: Mauro Cappelletti.

Medicina d’Urgenza e Pronto Soccorso, Università Cattolica del Sacro Cuore, Policlinico A. Gemelli, Roma: Nicolò Gentiloni-Silveri.

### Appendix Table 1. Risk Stratification (Incident Cases Only)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Community-Acquired Pneumonia (95% CI), % (n = 97)</th>
<th>Health Care–Associated Pneumonia (95% CI), % (n = 31)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean PSI score</td>
<td>105.9 (98.6–113.2)</td>
<td>122.0 (112–132)</td>
<td>0.010</td>
</tr>
<tr>
<td>PSI high-risk class*</td>
<td>68.0 (58.7–77.4)</td>
<td>97.8 (90.5–100)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CURB-65 high-risk score†</td>
<td>11.3 (4.5–18.2)</td>
<td>32.2 (16.3–48.2)</td>
<td>0.090</td>
</tr>
</tbody>
</table>

CURB-65 = Confusion, Urea nitrogen, Respiratory rate, Blood pressure, and age 65 years or older; PSI = Pneumonia Severity Index.

* Class IV or V (8).
† Class III (9).

### Appendix Table 2. Patient Characteristics (Incident Cases Only)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Community-Acquired Pneumonia (n = 97)</th>
<th>Health Care–Associated Pneumonia (n = 31)</th>
<th>Hospital-Acquired Pneumonia (n = 16)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men, %</td>
<td>61.8</td>
<td>64.5</td>
<td>68.7</td>
<td>0.89</td>
</tr>
<tr>
<td>Mean age, y</td>
<td>70.8</td>
<td>77.4</td>
<td>79.7</td>
<td>0.28</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease, %</td>
<td>42.3</td>
<td>41.9</td>
<td>25</td>
<td>0.45</td>
</tr>
<tr>
<td>Heart failure, %</td>
<td>22.7</td>
<td>38.7</td>
<td>18.7</td>
<td>0.190</td>
</tr>
<tr>
<td>Dementia, %</td>
<td>22.7</td>
<td>16.1</td>
<td>37.5</td>
<td>0.25</td>
</tr>
<tr>
<td>Renal failure, %</td>
<td>14.4</td>
<td>29</td>
<td>18.7</td>
<td>0.170</td>
</tr>
<tr>
<td>Diabetes mellitus, %</td>
<td>15.5</td>
<td>22.6</td>
<td>25</td>
<td>0.47</td>
</tr>
<tr>
<td>Cancer, %</td>
<td>14.4</td>
<td>32.2</td>
<td>25</td>
<td>0.070</td>
</tr>
<tr>
<td>Chronic liver disease, %</td>
<td>9.3</td>
<td>12.9</td>
<td>12.5</td>
<td>0.69</td>
</tr>
<tr>
<td>&gt;2 comorbid conditions, %</td>
<td>14.4</td>
<td>32.2</td>
<td>31.2</td>
<td>0.030</td>
</tr>
<tr>
<td>Endotracheal intubation in the past 30 days, %</td>
<td>0</td>
<td>3.2</td>
<td>12.5</td>
<td>0.009</td>
</tr>
<tr>
<td>Leukopenia, %</td>
<td>4.1</td>
<td>3.2</td>
<td>6.2</td>
<td>0.82</td>
</tr>
<tr>
<td>Malnutrition, %</td>
<td>6.2</td>
<td>16.1</td>
<td>25</td>
<td>0.020</td>
</tr>
<tr>
<td>Histamine-2 blockers or antacids, %</td>
<td>20.6</td>
<td>48.4</td>
<td>68.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Tracheostomy, %</td>
<td>0</td>
<td>3.2</td>
<td>12.5</td>
<td>0.009</td>
</tr>
<tr>
<td>Aerosolized drugs, %</td>
<td>15.5</td>
<td>25.8</td>
<td>25</td>
<td>0.29</td>
</tr>
<tr>
<td>Previous antibiotic therapy, %</td>
<td>33</td>
<td>38.7</td>
<td>50</td>
<td>0.41</td>
</tr>
<tr>
<td>Fever, %</td>
<td>62.9</td>
<td>38.7</td>
<td>56.2</td>
<td>0.060</td>
</tr>
<tr>
<td>Depression of consciousness, %</td>
<td>17.5</td>
<td>35.5</td>
<td>43.7</td>
<td>0.010</td>
</tr>
<tr>
<td>Dyspnea, %</td>
<td>68</td>
<td>77.7</td>
<td>50</td>
<td>0.38</td>
</tr>
<tr>
<td>Cough, %</td>
<td>57.7</td>
<td>48.4</td>
<td>43.7</td>
<td>0.45</td>
</tr>
<tr>
<td>Purulent sputum, %</td>
<td>30.9</td>
<td>38.7</td>
<td>25</td>
<td>0.62</td>
</tr>
<tr>
<td>Pleuritic chest pain, %</td>
<td>20.6</td>
<td>6.4</td>
<td>6.2</td>
<td>0.100</td>
</tr>
<tr>
<td>Leukocytosis, %</td>
<td>63.9</td>
<td>48.4</td>
<td>56.2</td>
<td>0.25</td>
</tr>
<tr>
<td>Bilateral involvement on chest radiograph, %</td>
<td>16.5</td>
<td>45.2</td>
<td>25</td>
<td>0.005</td>
</tr>
<tr>
<td>Multilobar infiltrates, %</td>
<td>22.7</td>
<td>25.8</td>
<td>43.7</td>
<td>0.21</td>
</tr>
<tr>
<td>Pleural effusion, %</td>
<td>42.3</td>
<td>38.7</td>
<td>37.5</td>
<td>0.90</td>
</tr>
<tr>
<td>Mean SOFA score</td>
<td>1.84</td>
<td>3.38</td>
<td>3.37</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Microbiological diagnosis, %</td>
<td>15.5</td>
<td>35.5</td>
<td>18.7</td>
<td>0.060</td>
</tr>
</tbody>
</table>

SOFA = Sequential Organ Failure Assessment.

### Appendix Table 3. Antimicrobial Therapy and Outcomes (Incident Cases Only)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Community-Acquired Pneumonia (n = 97)</th>
<th>Health Care–Associated Pneumonia (n = 31)</th>
<th>Hospital-Acquired Pneumonia (n = 16)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial antibiotic monotherapy (95% CI), %</td>
<td>53.1 (41.7 to 64.5)</td>
<td>66.7 (49.1 to 84.2)</td>
<td>43.7 (21.8 to 65.7)</td>
<td>0.27</td>
</tr>
<tr>
<td>Adherence to international guidelines (95% CI), %</td>
<td>59.8 (50.3 to 69.3)</td>
<td>35.5 (18.4 to 52.6)</td>
<td>50 (27.8 to 72.2)</td>
<td>0.060</td>
</tr>
<tr>
<td>Inappropriate antibiotic therapy (95% CI), %</td>
<td>4.1 (0.3 to 8.9)</td>
<td>16.1 (0 to 32.2)</td>
<td>6.2 (3.8 to 16.3)</td>
<td>0.080</td>
</tr>
<tr>
<td>Mean duration of antibiotic therapy (95% CI), d</td>
<td>12.8 (11.5 to 14.1)</td>
<td>14.4 (11.9 to 16.9)</td>
<td>11.4 (8.8 to 14)</td>
<td>0.47</td>
</tr>
<tr>
<td>Mean duration of hospitalization (95% CI), d</td>
<td>12.5 (11 to 13.9)</td>
<td>15.9 (10.6 to 21.1)</td>
<td>14.7 (10.1 to 19.3)</td>
<td>0.58</td>
</tr>
<tr>
<td>Overall in-hospital mortality rate (95% CI), %</td>
<td>7.2 (2.4 to 12)</td>
<td>22.6 (9.6 to 35.5)</td>
<td>18.7 (2.2 to 39.7)</td>
<td>0.040</td>
</tr>
</tbody>
</table>